Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics

Arq Bras Cardiol. 2015 Dec;105(6):597-605. doi: 10.5935/abc.20150123. Epub 2015 Oct 2.
[Article in English, Portuguese]

Abstract

Background: Studies suggest that statins have pleiotropic effects, such as reduction in blood pressure, and improvement in endothelial function and vascular stiffness.

Objective: To analyze if prior statin use influences the effect of renin-angiotensin-aldosterone system inhibitors on blood pressure, endothelial function, and vascular stiffness.

Methods: Patients with diabetes and hypertension with office systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 80 mmHg had their antihypertensive medications replaced by amlodipine during 6 weeks. They were then randomized to either benazepril or losartan for 12 additional weeks while continuing on amlodipine. Blood pressure (assessed with ambulatory blood pressure monitoring), endothelial function (brachial artery flow-mediated dilation), and vascular stiffness (pulse wave velocity) were evaluated before and after the combined treatment. In this study, a post hoc analysis was performed to compare patients who were or were not on statins (SU and NSU groups, respectively).

Results: The SU group presented a greater reduction in the 24-hour systolic blood pressure (from 134 to 122 mmHg, p = 0.007), and in the brachial artery flow-mediated dilation (from 6.5 to 10.9%, p = 0.003) when compared with the NSU group (from 137 to 128 mmHg, p = 0.362, and from 7.5 to 8.3%, p = 0.820). There was no statistically significant difference in pulse wave velocity (SU group: from 9.95 to 9.90 m/s, p = 0.650; NSU group: from 10.65 to 11.05 m/s, p = 0.586).

Conclusion: Combined use of statins, amlodipine, and renin-angiotensin-aldosterone system inhibitors improves the antihypertensive response and endothelial function in patients with hypertension and diabetes.

Trial registration: ClinicalTrials.gov NCT01603940.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acids / pharmacology*
  • Amino Acids / therapeutic use
  • Amlodipine / pharmacology
  • Amlodipine / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antihypertensive Agents / pharmacology*
  • Antihypertensive Agents / therapeutic use
  • Benzazepines / pharmacology
  • Benzazepines / therapeutic use
  • Blood Pressure / drug effects
  • Blood Pressure Monitoring, Ambulatory
  • Brachial Artery / drug effects
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiology
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Losartan / pharmacology
  • Losartan / therapeutic use
  • Male
  • Middle Aged
  • Pulse Wave Analysis
  • Renin-Angiotensin System / drug effects*
  • Statistics, Nonparametric
  • Time Factors
  • Treatment Outcome
  • Vascular Stiffness / drug effects

Substances

  • Amino Acids
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Benzazepines
  • Amlodipine
  • Losartan
  • benazepril
  • statine

Associated data

  • ClinicalTrials.gov/NCT01603940